Dear Reader :

This month’s edition of Citeline’s newsletter, developed in alliance with the IPA, spotlights key sectoral trends and specialisms to keep an eye on.

A senior executive of Novo Holdings Equity US Inc talks about Korea’s strong engineering culture that makes it adept at developing a Version 2.0 of new drug modalities, while the CEO of a Switzerland-based CDMO points to the increasing complexity of personalized medicines that has impacted manufacturing trends.

We also roundup the M&A action in the first half of 2023 - bolt-on deals remain in vogue.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA


Perspective From Industry Leaders
Novo Holdings’ Jee On Korea's Potential As Next Global Biotech Player Ex-Roche Executive Mahler On Past, Present And Future Of Swiss CDMOs
Novo Holdings’ Jee On Korea's Potential As Next Global Biotech Player Ex-Roche Executive Mahler On Past, Present And Future Of Swiss CDMOs

In this video interview, Novo Holdings’ Noel Jee shares his views on the Korean biotech industry and innovation, including how to draw more foreign ...

During a broad and wide-ranging interview, taking place in the aftermath of Fresenius Kabi’s entry into the US adalimumab biosimilar market ...
 
Licensing & Collaboration Agreements
Despite Pfizer/Seagen’s Splash, Deals Are Staying Small Stada’s Owners Hold ‘Initial Exploratory Talks’ For Potential Sale
Despite Pfizer/Seagen’s Splash, Deals Are Staying Small Stada’s Owners Hold ‘Initial Exploratory Talks’ For Potential Sale

Although late 2022 and early 2023 saw a few large transactions, a look at deal activity in the first half of the year shows bolt-on M&A remains in vogue for ...

For the first time, privately-owned Stada has acknowledged the potential for a sale of the business – six years after the private equity duo Bain Capital and ...
Next Gen R&D
With $175m, Mariana Will Take First Precision Radiopharmaceutical Into The Clinic Seagen And Nurix Hope To Pioneer A New Class Of Degrader-Antibody Conjugates
With $175m, Mariana Will Take First Precision Radiopharmaceutical Into The Clinic Seagen And Nurix Hope To Pioneer A New Class Of Degrader-Antibody Conjugates

Mariana Oncology closed a $175m series A venture capital round to fund its first clinical trial, for MC-339 in small-cell lung cancer, as well as its ...

The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front ...
Clinical Trials
CymaBay’s Seladelpar Hits Three Endpoints In Phase III PBC Study EU Project To Evaluate Delays To Drug Trials Conducted Alongside Studies For IVDs/Devices
CymaBay’s Seladelpar Hits Three Endpoints In Phase III PBC Study EU Project To Evaluate Delays To Drug Trials Conducted Alongside Studies For IVDs/Devices

Seladelpar may threaten an entrenched second-line therapy, Intercept’s Ocaliva, with better efficacy, based on benefits demonstrated ....

The European Commission is steering a new member state-driven project that aims to get to the bottom of factors causing delays to trials that ...
Citeline Contact

Poornachandra Tejasvi .K,
Senior Director - Emerging Markets, India
Mobile: +91 9945273146
Email: poornachandra.tejasvi@citeline.com
Client Services: clientservices@citeline.com

alt_text   alt_text 		IPA Contact

Name: Hari Pranav K
Email: haripranav.k@ipa-india.org